AR011759A1 - Compuesto derivado de fenoximetilpiperidina, procedimientos para su preparacion, una composicion farmaceutica, el uso del mismo para la preparacion de un medicamento, para la preparacion de un producto intermedio, un solvato y un envase - Google Patents

Compuesto derivado de fenoximetilpiperidina, procedimientos para su preparacion, una composicion farmaceutica, el uso del mismo para la preparacion de un medicamento, para la preparacion de un producto intermedio, un solvato y un envase

Info

Publication number
AR011759A1
AR011759A1 ARP990101885A ARP990101885A AR011759A1 AR 011759 A1 AR011759 A1 AR 011759A1 AR P990101885 A ARP990101885 A AR P990101885A AR P990101885 A ARP990101885 A AR P990101885A AR 011759 A1 AR011759 A1 AR 011759A1
Authority
AR
Argentina
Prior art keywords
preparation
phenoxymethylpiperidine
solvate
procedures
container
Prior art date
Application number
ARP990101885A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011759(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814316.7A external-priority patent/GB9814316D0/en
Priority claimed from GBGB9821732.6A external-priority patent/GB9821732D0/en
Priority claimed from GBGB9902935.7A external-priority patent/GB9902935D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR011759A1 publication Critical patent/AR011759A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP990101885A 1998-07-02 1999-04-23 Compuesto derivado de fenoximetilpiperidina, procedimientos para su preparacion, una composicion farmaceutica, el uso del mismo para la preparacion de un medicamento, para la preparacion de un producto intermedio, un solvato y un envase AR011759A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds
GBGB9821732.6A GB9821732D0 (en) 1998-10-06 1998-10-06 Novel compound
GBGB9902935.7A GB9902935D0 (en) 1999-02-10 1999-02-10 Novel compound

Publications (1)

Publication Number Publication Date
AR011759A1 true AR011759A1 (es) 2000-09-13

Family

ID=27269380

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990101885A AR011759A1 (es) 1998-07-02 1999-04-23 Compuesto derivado de fenoximetilpiperidina, procedimientos para su preparacion, una composicion farmaceutica, el uso del mismo para la preparacion de un medicamento, para la preparacion de un producto intermedio, un solvato y un envase
ARP990101908A AR018197A1 (es) 1998-07-02 1999-04-26 Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP990101908A AR018197A1 (es) 1998-07-02 1999-04-26 Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento

Country Status (34)

Country Link
US (4) US6063927A (enExample)
EP (5) EP0970955B1 (enExample)
JP (1) JP2002519422A (enExample)
KR (1) KR20010053336A (enExample)
CN (1) CN1127502C (enExample)
AR (2) AR011759A1 (enExample)
AT (4) ATE251155T1 (enExample)
AU (4) AU713877B3 (enExample)
BE (3) BE1012403A5 (enExample)
BR (1) BR9911682A (enExample)
CA (1) CA2269999A1 (enExample)
CH (1) CH689805A8 (enExample)
DE (5) DE69911774T2 (enExample)
DK (7) DK199900176U3 (enExample)
ES (4) ES2209428T3 (enExample)
FI (2) FI4209U1 (enExample)
FR (2) FR2780728B1 (enExample)
GB (5) GB2339428A (enExample)
GR (3) GR990100140A (enExample)
HU (1) HUP0102334A3 (enExample)
IE (5) IE20000633A1 (enExample)
IL (1) IL140628A (enExample)
IT (1) IT1312540B1 (enExample)
LU (1) LU90388B1 (enExample)
NL (4) NL1011875C2 (enExample)
NO (1) NO319030B1 (enExample)
NZ (1) NZ509180A (enExample)
PL (1) PL345214A1 (enExample)
PT (4) PT1089996E (enExample)
SE (1) SE9901462A0 (enExample)
SI (3) SI1089996T1 (enExample)
SK (1) SK20262000A3 (enExample)
TR (1) TR200100054T2 (enExample)
WO (1) WO2000001694A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
WO1998037938A1 (en) * 1997-02-27 1998-09-03 Ajinomoto Co., Inc. Crystallization apparatus and crystallization method
KR100543614B1 (ko) * 1997-06-10 2006-01-20 신톤 비.브이. 4-페닐피페리딘 화합물
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20040028582A1 (en) * 1999-03-10 2004-02-12 Smithkline Beecham Corporation Crystallization process for producing fine crystal products
USPP12225P2 (en) 1999-06-01 2001-11-27 Florfis Ag Geranium plant named ‘Fislamda’
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
HUP0303827A2 (hu) * 2000-08-28 2004-04-28 Synthon B.V. Paroxetinkészítmények és eljárások ezek előállítására
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
US20040225128A1 (en) * 2001-08-02 2004-11-11 Callewaert George Leo Paroxetine isethionate salt, process of preparation and use in the treatment of depression
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
EP1874908B1 (en) 2005-04-07 2014-06-11 Xy, Llc Method for reducing microorganisms in a flow path using diacetone alcohol
CA2629514A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US8722884B2 (en) * 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
CA2679484A1 (en) * 2007-03-09 2008-09-18 Novartis Ag Salts of 3-(1h-ind0l-3-yl)-4-[2-(4-methyl-piperazin-i-yl)-quinazolin-4-yl]-pyrrole-2,5-dione
US20100249166A1 (en) 2007-09-19 2010-09-30 Xy, Inc. Differential evaporation potentiated disinfectant system
US8119688B2 (en) * 2007-09-19 2012-02-21 Xy, Llc Differential evaporation potentiated disinfectant system
FR2926552B1 (fr) * 2008-01-23 2010-03-26 Biocodex Procede de preparation de particules de stiripentol ayant une granulometrie definie
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法
CN104523645A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 甲磺酸帕罗西汀片芯及其包衣片的制备方法
US11111373B2 (en) 2018-12-05 2021-09-07 Chi Mei Corporation Polymethacrylate composition and optical device made therefrom, and display apparatus

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE99678C (enExample) *
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
GB8431478D0 (en) * 1984-12-13 1985-01-23 Beecham Group Plc Compounds
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
EP0223334B1 (en) * 1985-08-10 1991-07-10 Beecham Group Plc Process for the preparation of aryl-piperidine carbinols
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
DE3677712D1 (de) * 1985-10-21 1991-04-04 Honda Motor Co Ltd Methode zur steuerung des spulenstroms eines magnetventils, das die saufluftmenge eines innenverbrennungsmotors steuert.
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
WO1992009281A2 (en) * 1990-11-24 1992-06-11 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
GB2297550C2 (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
NZ307479A (en) * 1995-05-17 1999-08-30 Novo Nordisk As A process for preparing 4-(4-halo substituted phenyl)-3-(3,4-methylenedioxy phenoxy methyl)piperidine derivatives
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
AU701386B2 (en) * 1995-10-31 1999-01-28 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1384720A1 (en) * 1996-06-13 2004-01-28 SUMIKA FINE CHEMICALS Co., Ltd. Process for drying paroxetine hydrochloride
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
KR100543614B1 (ko) * 1997-06-10 2006-01-20 신톤 비.브이. 4-페닐피페리딘 화합물
KR20010040711A (ko) * 1998-02-06 2001-05-15 피터 기딩스 파록세틴의 염
BR9908825A (pt) * 1998-03-16 2000-11-21 Smithkline Beecham Plc Forma cristalina de paroxetina
JP2002511466A (ja) * 1998-04-09 2002-04-16 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー マレイン酸パロキセチン
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat

Also Published As

Publication number Publication date
NO991944D0 (no) 1999-04-23
HUP0102334A2 (hu) 2002-05-29
FI990922A0 (fi) 1999-04-23
EP1020463A1 (en) 2000-07-19
DE69900007D1 (de) 2000-09-07
IL140628A (en) 2004-06-20
SK20262000A3 (sk) 2001-07-10
ITMI990866A1 (it) 2000-10-23
DK1089996T3 (da) 2004-02-09
EP1089996A1 (en) 2001-04-11
BE1011664A6 (fr) 1999-11-09
CN1127502C (zh) 2003-11-12
DK200000390U1 (da) 2000-12-27
DK199900234U4 (da) 2000-12-22
ES2158778B1 (es) 2002-03-16
GB2352395B (en) 2004-02-11
ES2158778A1 (es) 2001-09-01
DE69900007T2 (de) 2001-06-07
FI4209U1 (fi) 1999-11-10
NL1012271C2 (nl) 1999-09-23
ATE195121T1 (de) 2000-08-15
DE60000003D1 (de) 2001-08-09
DE29907248U1 (de) 1999-09-09
SI1020464T1 (en) 2001-12-31
AR018197A1 (es) 2001-10-31
EP0970955A1 (en) 2000-01-12
SI1089996T1 (en) 2004-04-30
CA2269999A1 (en) 2000-01-02
EP1020464A1 (en) 2000-07-19
CH689805A8 (fr) 2000-02-29
LU90388B1 (fr) 2001-01-29
SE9901462D0 (sv) 1999-04-23
GB2336364B (en) 2000-05-10
NL1011875A1 (nl) 2000-01-07
DE60000003T2 (de) 2002-03-21
GB0026487D0 (en) 2000-12-13
DK199900234U1 (da) 2000-12-22
TR200100054T2 (tr) 2001-06-21
AU3619199A (en) 2000-01-24
ES2209428T3 (es) 2004-06-16
FR2802098A1 (fr) 2001-06-15
JP2002519422A (ja) 2002-07-02
FIU990190U0 (fi) 1999-04-23
GB2352395A (en) 2001-01-31
ES2149044T3 (es) 2000-10-16
AU732211C (en) 2004-05-06
EP0970955B1 (en) 2000-08-02
EP1020464B1 (en) 2001-07-04
SE9901462L (enExample)
GR990100140A (el) 2000-03-31
GR3034328T3 (en) 2000-12-29
PT102291A (pt) 2000-05-31
AU2392899A (en) 2000-01-20
GR1003350B (el) 2000-03-29
DE19918588A1 (de) 2000-01-27
GB2367003A (en) 2002-03-27
NL1011875C2 (nl) 2000-03-24
AT3185U2 (de) 1999-11-25
GB2377637A (en) 2003-01-22
GB2336364A (en) 1999-10-20
IE20000633A1 (en) 2001-10-17
US20020035130A1 (en) 2002-03-21
CN1315949A (zh) 2001-10-03
AU713877B3 (en) 1999-12-09
CH689805A5 (fr) 1999-11-30
ATE202777T1 (de) 2001-07-15
GB0119695D0 (en) 2001-10-03
GB0216752D0 (en) 2002-08-28
WO2000001694A1 (en) 2000-01-13
ES2157881T3 (es) 2001-09-01
BE1012403A5 (fr) 2000-10-03
SE9901462A0 (sv) 2000-01-03
PT970955E (pt) 2000-11-30
HK1037877A1 (en) 2002-02-22
BE1012420A6 (fr) 2000-10-03
IES20000893A2 (en) 2001-05-30
FI990922L (fi) 2000-01-03
FR2780728B1 (fr) 2001-02-16
PL345214A1 (en) 2001-12-03
AU732211B2 (en) 2001-04-12
KR20010053336A (ko) 2001-06-25
NZ509180A (en) 2001-06-29
NL1011874C1 (nl) 1999-07-12
ATE251155T1 (de) 2003-10-15
DK199900176U3 (da) 1999-08-13
DK0970955T3 (da) 2000-10-09
GB9920332D0 (en) 1999-11-03
IES20000894A2 (en) 2001-05-30
GB9909505D0 (en) 1999-06-23
NL1012272C1 (nl) 1999-07-12
AU713131B3 (en) 1999-11-25
BR9911682A (pt) 2001-12-26
GB2339428A (en) 2000-01-26
IT1312540B1 (it) 2002-04-22
AT3185U3 (de) 2000-01-25
FI112077B (fi) 2003-10-31
IES990343A2 (en) 2000-01-02
EP1288214A1 (en) 2003-03-05
NL1012271A1 (nl) 1999-07-12
PT1089996E (pt) 2004-02-27
DK199900554A (da) 2000-01-03
US6063927A (en) 2000-05-16
FR2780728A1 (fr) 2000-01-07
PT102291B (pt) 2002-07-31
GR3036208T3 (en) 2001-10-31
EP1089996B1 (en) 2003-10-01
NO319030B1 (no) 2005-06-06
DK1020464T3 (da) 2001-09-24
SI0970955T1 (en) 2001-02-28
US20010023253A1 (en) 2001-09-20
IES81166B2 (en) 2000-05-31
PT1020464E (pt) 2001-10-30
HUP0102334A3 (en) 2003-12-29
US20020193406A1 (en) 2002-12-19
IE990344A1 (en) 2000-05-03
NO991944L (no) 2000-01-03
DE69911774T2 (de) 2004-08-05
DE69911774D1 (de) 2003-11-06
IL140628A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
AR011759A1 (es) Compuesto derivado de fenoximetilpiperidina, procedimientos para su preparacion, una composicion farmaceutica, el uso del mismo para la preparacion de un medicamento, para la preparacion de un producto intermedio, un solvato y un envase
MY106315A (en) Pharmaceutical agents
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
CA2385890A1 (en) Controlled release compositions comprising nimesulide
FR2805818B1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
DE69225421D1 (de) Sumatriptan enthaltende Arzneimittel
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
DE60008374D1 (de) Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten
HUP0201275A3 (en) Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts and pharmaceutical composition containing the compound
GB0109122D0 (en) Novel compounds
DE69923336D1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
SE8804628D0 (sv) New compounds
WO1998008517A3 (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
CO5261595A1 (es) Composiciones farmaceuticas que contienen una combinacion de salmeterol e ipratropium
EP0410114A3 (en) Use of 4-(4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl)-1-(4-fluorophenyl)-butanol in pharmaceutical compositions for the treatment of ischemia in brain
AR006281A1 (es) Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares
HUT50787A (en) Process for producing pharmaceutical compositions comprising 4-aryl-4-piperidine-, pyrrolidine- or hexahydroazepincarbinol derivatives or heterocyclic analogs thereof as active ingredient and process for producing the new compounds
HUP0400889A2 (hu) Eljárások (R)-alfa-(2,3-dimetoxi-fenil)-1-[2-(4-fluor-fenil)-etil]-4-piperidin-metanol előállítására és a vegyületet tartalmazó gyógyszerkészítmények
SE0001916D0 (sv) Novel formulation
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
NZ508325A (en) Microemulsion preconcentrates for oral administration containing a piperidine substance P antagonist
AR023563A1 (es) Monohidrato de hidrocloruro de un derivado de tiazolidin-2,4-diona, una composicion farmaceutica y el uso del mismo para la fabricacion de un medicamento

Legal Events

Date Code Title Description
FC Refusal